Expert review of respiratory medicine最新文献_第6页

Unmet challenges in cystic fibrosis treatment with modulators. 使用调节剂治疗囊性纤维化方面尚未解决的难题。

Expert review of respiratory medicine Pub Date : 2024-05-16 DOI: 10.1080/17476348.2024.2357210

Federica Corrao, Mairead Kelly-Aubert, Isabelle Sermet-Gaudelus, Michaela Semeraro

{"title":"Unmet challenges in cystic fibrosis treatment with modulators.","authors":"Federica Corrao, Mairead Kelly-Aubert, Isabelle Sermet-Gaudelus, Michaela Semeraro","doi":"10.1080/17476348.2024.2357210","DOIUrl":"https://doi.org/10.1080/17476348.2024.2357210","url":null,"abstract":"INTRODUCTION\u0000'Highly effective' modulator therapies (HEMTs) have radically changed the Cystic Fibrosis (CF) therapeutic landscape. These novel therapeutic approaches have permitted unprecedented opportunities for quality-of-life improvement and for enhancing people with CF's (pwCF) life expectancy.\u0000\u0000\u0000AREAS COVERED\u0000The aim of this review is to describe the current knowledge gaps. A comprehensive search strategy was undertaken to assess impact of HEMT in life of pwCF, treatment challenges in specific populations such as very young children, and research needs.\u0000\u0000\u0000EXPERT OPINION\u0000HEMTs are prescribed for pwCF with definite genotypes. The heterogeneity of variants complicates treatment possibilities and around 10% of pwCF worldwide remains ineligible. Genotype-specific treatments are prompting theratyping and personalized medicine strategies. Improvement in lung function and quality of life increase survival rates, shifting CF from a pediatric to an adult disease. This implies new studies addressing long-term efficacy, side effects, emergence of adult co-morbidities and possible drug-drug interactions. More sensitive and predictive biomarkers for both efficacy and toxicity are warranted. As HEMTs cross the placenta and are found in breast milk, studies addressing the potential consequences of treatment during pregnancy and breastfeeding are urgently needed. Finally, although the treatment and expected outcomes of CF have improved dramatically in high- and middle-income countries, lack of access in low-income countries to these lifesaving and life-changing medicines highlights inequity of care worldwide.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":"116 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140967893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Non-specific pleuritis: long-term follow-up outcomes. 非特异性胸膜炎：长期随访结果。

Expert review of respiratory medicine Pub Date : 2024-05-01 Epub Date: 2024-06-20 DOI: 10.1080/17476348.2024.2368610

Lucía Ferreiro, Elisa Landín Rey, María Carreiras Cuiña, Francisco Gude, José R Antúnez, Juan Suárez-Antelo, María Elena Toubes, Nuria Rodríguez Núñez, Antonio Golpe, Vanessa Riveiro, Luis Valdés

{"title":"Non-specific pleuritis: long-term follow-up outcomes.","authors":"Lucía Ferreiro, Elisa Landín Rey, María Carreiras Cuiña, Francisco Gude, José R Antúnez, Juan Suárez-Antelo, María Elena Toubes, Nuria Rodríguez Núñez, Antonio Golpe, Vanessa Riveiro, Luis Valdés","doi":"10.1080/17476348.2024.2368610","DOIUrl":"10.1080/17476348.2024.2368610","url":null,"abstract":"Background: The definitive etiology of nonspecific pleuritis (NSP), the influence of the type of pleural biopsy on clinical results and the minimum duration of follow-up is controversial.Research design and methods: A retrospective, observational study of patients ≥ 18 years with NSP confirmed by closed pleural biopsy (CPB), local anesthesia pleuroscopy (LAP), or video-assisted thoracic surgery (VATS).Results: A total of 167 patients were included (mean follow-up, 14.4 months), of which 25 (15%) were diagnosed within one month; [15 (60%) malignant]. Of the remaining 142 pleural effusions (PEf), 69 (48.6%) were idiopathic; 49 (34.5%) not-malignant and 24 (16.9%) malignant (4 mesotheliomas and 20 metastasic). The diagnosis of NSP was established by CPB (7; median time to diagnosis, 9.4 months), LAT (5; 15.8 months), and VATS (8; 13.5 months) (p = 0.606). Sixty-eight patients (40.7%) died during follow-up (mean time, 12 months).Conclusions: In a substantial percentage of patients diagnosed with NSP, a definitive diagnosis will not be obtained, a relevant number of patients will develop a malignant PEf. The diagnostic procedure used for the diagnosis of NSP does not seem to influence delay in the diagnosis of malignant PEf. The data obtained suggest that follow-up should be maintained for at least 24 months.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"333-339"},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141328244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Developments in treatment for middle east respiratory syndrome coronavirus (MERS-CoV). 治疗中东呼吸综合征冠状病毒 (MERS-CoV) 的进展。

Expert review of respiratory medicine Pub Date : 2024-05-01 Epub Date: 2024-06-21 DOI: 10.1080/17476348.2024.2369714

Jaffar A Al-Tawfiq

{"title":"Developments in treatment for middle east respiratory syndrome coronavirus (MERS-CoV).","authors":"Jaffar A Al-Tawfiq","doi":"10.1080/17476348.2024.2369714","DOIUrl":"10.1080/17476348.2024.2369714","url":null,"abstract":"Introduction: An important respiratory pathogen that has led to multiple hospital outbreaks both inside and outside of the Arabian Peninsula is the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Given the elevated case fatality rate, there exists a pressing requirement for efficacious therapeutic agents.Areas covered: This is an updated review of the developments in MERS treatment approaches. Using databases like PubMed, Embase, Cochrane, Scopus, and Google Scholar, a thorough search was carried out utilizing keywords like 'MERS,' 'MERS-CoV,' and 'Middle East respiratory syndrome' in conjunction with 'treatment' or 'therapy' from Jan 2012 to Feb 2024.Expert opinion: MERS-CoV is a highly pathogenic respiratory infection that emerged in 2012 and continues to pose a significant public health threat. Despite ongoing efforts to control the spread of MERS-CoV, there is currently no specific antiviral treatment available. While many agents have been tested both in vivo and in vitro, none of them have been thoroughly examined in extensive clinical trials. Only case reports, case series, or cohort studies have been made available as clinical studies. However, there is a limited number of randomized-controlled trials. Because cases are irregular and sporadic, conducting a large prospective randomized trials for establishing an efficacious treatment might be difficult.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"295-307"},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141332744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Management of liver disease and portal hypertension in cystic fibrosis: a review. 囊性纤维化肝病和门静脉高压的管理：综述。

Expert review of respiratory medicine Pub Date : 2024-05-01 Epub Date: 2024-07-04 DOI: 10.1080/17476348.2024.2365842

Carla Colombo, Chiara Lanfranchi, Giulia Tosetti, Fabiola Corti, Massimo Primignani

{"title":"Management of liver disease and portal hypertension in cystic fibrosis: a review.","authors":"Carla Colombo, Chiara Lanfranchi, Giulia Tosetti, Fabiola Corti, Massimo Primignani","doi":"10.1080/17476348.2024.2365842","DOIUrl":"10.1080/17476348.2024.2365842","url":null,"abstract":"Introduction: Cystic fibrosis (CF)-associated liver disease can significantly affect the quality of life and survival of people with CF. The hepatobiliary manifestations in CF are various, with focal/multilobular biliary cirrhosis more common in children and porto-sinusoidal vascular disease (PSVD) in young adults. Portal hypertensive complications, particularly bleeding from esophagogastric varices and hypersplenism are common, while liver failure is rarer and mainly linked to biliary disease.Areas covered: This review explores current therapeutic options for CF-associated liver disease, presenting ongoing studies and new insights into parthenogenesis for potential future therapies.Expert opinion: Monitoring for signs of portal hypertension is essential. Limited evidence supports ursodeoxycholic acid (UDCA) efficacy in halting CF liver disease progression. The effect of cystic fibrosis transmembrane conductance regulator (CFTR) modulators on liver outcomes lacks definitive data, since patients with CF-related liver disease were excluded from trials due to potential hepatotoxicity. A proposed approach involves using UDCA and modulators in early stages, along with anti-inflammatory agents, with further therapeutic strategies awaiting randomized trials. Prevention of portal hypertensive bleeding includes endoscopic sclerotherapy or ligation of esophageal varices. Nonselective beta-blockers may also prevent bleeding and could be cautiously implemented. Other non-etiological treatments require investigation.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"269-281"},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141499984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mendelian randomization study on the causal effect of herpes simplex virus infection on idiopathic pulmonary fibrosis. 关于单纯疱疹病毒感染对特发性肺纤维化因果效应的孟德尔随机研究。

Expert review of respiratory medicine Pub Date : 2024-05-01 Epub Date: 2024-06-17 DOI: 10.1080/17476348.2024.2369253

Min Zhang, Jinming Qiu, Renxi Wang

{"title":"Mendelian randomization study on the causal effect of herpes simplex virus infection on idiopathic pulmonary fibrosis.","authors":"Min Zhang, Jinming Qiu, Renxi Wang","doi":"10.1080/17476348.2024.2369253","DOIUrl":"10.1080/17476348.2024.2369253","url":null,"abstract":"Background: Previous observational studies have shown that past infection of herpes simplex virus (HSV) is associated with idiopathic pulmonary fibrosis (IPF). The present study aims to identify the causal link between HSV infection (exposure factor) and IPF (outcome factor).Research design and methods: To date, the largest publicly available genome-wide association study (GWAS) for HSV infection (1,595 cases and 211,856 controls from Finnish ancestry) and for IPF (1,028 cases and 196,986 controls from Finnish ancestry) were used to perform this two-sample Mendelian randomization (MR) study.Results: We found no significant pleiotropy or heterogeneity of all selected nine HSV infection-associated genetic instrumental variants (IVs) in IPF GWAS dataset. Interestingly, we found that as HSV infection genetically increased, IPF risk increased based on an inverse-variance weighted (IVW) analysis (odds ratio [OR] = 1.280, 95% confidence interval [CI]: 1.048-1.563; p = 0.015) and weighted median (OR = 1.321, 95% CI: 1.032-1.692; p = 0.027).Conclusions: Our analysis suggests a causal effect of genetically increased HSV infection on IPF risk. Thus, HSV infection may be a potential risk factor for IPF.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"341-347"},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141328243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The effects of physical activity tele-counseling intervention on physical activity, functional performance, and quality of life in post-COVID-19 conditions: a randomized controlled trial. 体力活动远程咨询干预对后 COVID-19 条件下的体力活动、功能表现和生活质量的影响：随机对照试验。

Expert review of respiratory medicine Pub Date : 2024-05-01 Epub Date: 2024-06-11 DOI: 10.1080/17476348.2024.2363862

Zeliha Çelik, Nihan Kafa, Nevin A Güzel, Nurdan Köktürk

{"title":"The effects of physical activity tele-counseling intervention on physical activity, functional performance, and quality of life in post-COVID-19 conditions: a randomized controlled trial.","authors":"Zeliha Çelik, Nihan Kafa, Nevin A Güzel, Nurdan Köktürk","doi":"10.1080/17476348.2024.2363862","DOIUrl":"10.1080/17476348.2024.2363862","url":null,"abstract":"Background: This study aims to investigate the effectiveness of tele-counseling to promote physical activity in COVID-19 survivors at the persistent phase.Methods: Twenty-eight participants who suffered from COVID-19 were randomly assigned to intervention and control groups. Physical activity counseling was applied according to the transtheoretical model to the intervention group during 20 sessions. Second assessments were performed 6 weeks after the intervention. The physical activity, functional performance (4-meter gait speed; 4-MGS and 5-repetition Sit-To-Stand; STS test), exercise behavioral change and processes, quality of life, fatigue, mental health, severity of symptoms, and dyspnea were evaluated in groups.Results: The baseline demographic and clinical outcomes were similar (p > 0.05) except for physical role limitations and general health perceptions in groups. Five-repetition STS, 4-MGS, activity dyspnea, step counts, sitting time, physical role limitations, Exercise Processes of Change Scale (EPCS) total, and behavioral processes scores except for self-liberation significantly improved in the counseling group. Five-repetition STS, 4-MGS improved while dramatic relief, self reevaluation, self-liberation, and EPCS total scores deteriorated in the control group.Conclusions: The tele-counseling intervention contributes to improving physical activity, functional performance, behavioral change, quality of life, and decreasing common problems related to COVID-19. The results of the tele-counseling intervention are promising in post-COVID-19 conditions.Trial registration (clinicaltrials.gov): Registration ID: NCT04853966.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"321-331"},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141201575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Understanding the role of biological sex can optimize care and drug development in asthma. 了解生物性的作用可以优化哮喘的护理和药物开发。

Expert review of respiratory medicine Pub Date : 2024-05-01 Epub Date: 2024-06-17 DOI: 10.1080/17476348.2024.2369250

Neeloffer Mookherjee, Christopher Carlsten

引用次数: 0

Central sleep apnea: emphasizing recognition and differentiation. 中枢性睡眠呼吸暂停：强调识别和区分。

Expert review of respiratory medicine Pub Date : 2024-05-01 Epub Date: 2024-06-18 DOI: 10.1080/17476348.2024.2369256

Dries Testelmans, Alexandros Kalkanis, Dimitrios Papadopoulos, Saartje Demolder, Bertien Buyse

{"title":"Central sleep apnea: emphasizing recognition and differentiation.","authors":"Dries Testelmans, Alexandros Kalkanis, Dimitrios Papadopoulos, Saartje Demolder, Bertien Buyse","doi":"10.1080/17476348.2024.2369256","DOIUrl":"10.1080/17476348.2024.2369256","url":null,"abstract":"Introduction: Central sleep apnea (CSA) is a sleep-related breathing disorder in which the effort to breathe is intermittently diminished or absent. CSA is a common disorder among patients with different cardiovascular disorders, including heart failure. In addition, a growing number of medications have been shown to induce CSA and CSA can emerge after initiation of treatment for obstructive sleep apnea. Accumulating evidence shows that CSA is a heterogeneous disorder with individual differences in clinical and biological characteristics and/or underlying pathophysiological mechanisms.Areas covered: This narrative review offers an overview of the diagnostic aspects and classification of CSA, with an emphasis on heart failure patients, patients with CSA due to a medication and treatment-emergent CSA. The importance of evaluation of prognostic biomarkers in patients with different types of CSA is discussed. This narrative review synthesizes literature on CSA sourced from the PubMed database up to February 2024.Expert opinion: CSA presents a remarkably diverse disorder, with treatment modalities exhibiting potentially varied efficacy across its various phenotypes. This highlights the imperative for tailored management strategies that are rooted in phenotype classification.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"309-320"},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141328242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The impact of smoking on bronchiectasis and its comorbidities. 吸烟对支气管扩张及其合并症的影响。

Expert review of respiratory medicine Pub Date : 2024-05-01 Epub Date: 2024-06-24 DOI: 10.1080/17476348.2024.2369716

David de la Rosa-Carrillo, José Ignacio de Granda-Orive, Layla Diab Cáceres, Fernando Gutiérrez Pereyra, Beatriz Raboso Moreno, Miguel-Ángel Martínez-García, Guillermo Suárez-Cuartin

{"title":"The impact of smoking on bronchiectasis and its comorbidities.","authors":"David de la Rosa-Carrillo, José Ignacio de Granda-Orive, Layla Diab Cáceres, Fernando Gutiérrez Pereyra, Beatriz Raboso Moreno, Miguel-Ángel Martínez-García, Guillermo Suárez-Cuartin","doi":"10.1080/17476348.2024.2369716","DOIUrl":"10.1080/17476348.2024.2369716","url":null,"abstract":"Introduction: Bronchiectasis, characterized by irreversible bronchial dilatation, is a growing global health concern with significant morbidity. This review delves into the intricate relationship between smoking and bronchiectasis, examining its epidemiology, pathophysiology, clinical manifestations, and therapeutic approaches. Our comprehensive literature search on PubMed utilized MESH terms including 'smoking,' 'smoking cessation,' 'bronchiectasis,' and 'comorbidities' to gather relevant studies.Areas covered: This review emphasizes the role of smoking in bronchiectasis development and exacerbation by compromising airways and immune function. Interconnected comorbidities, including chronic obstructive pulmonary disease, asthma, and gastroesophageal reflux disease, create a detrimental cycle affecting patient outcomes. Despite limited studies on smoking cessation in bronchiectasis, the review stresses its importance. Advocating for tailored cessation programs, interventions like drainage, bronchodilators, and targeted antibiotics are crucial to disrupting the inflammatory-infection-widening cycle.Expert opinion: The importance of smoking cessation in bronchiectasis management is paramount due to its extensive negative impact on related conditions. Proactive cessation programs utilizing technology and targeted education for high-risk groups aim to reduce smoking's impact on disease progression and related comorbidities. In conclusion, a personalized approach centered on smoking cessation is deemed vital for bronchiectasis, aiming to improve outcomes and enhance patients' quality of life in the face of this complex respiratory condition.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"255-268"},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141422261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Improving early diagnosis of bronchopulmonary dysplasia. 改善支气管肺发育不良的早期诊断。

Expert review of respiratory medicine Pub Date : 2024-05-01 Epub Date: 2024-06-14 DOI: 10.1080/17476348.2024.2367584

Oishi Sikdar, Christopher Harris, Anne Greenough

{"title":"Improving early diagnosis of bronchopulmonary dysplasia.","authors":"Oishi Sikdar, Christopher Harris, Anne Greenough","doi":"10.1080/17476348.2024.2367584","DOIUrl":"10.1080/17476348.2024.2367584","url":null,"abstract":"Introduction: Bronchopulmonary disease (BPD) is associated with long-term neurodevelopmental and cardiorespiratory complications, often requiring significant use of resources. To reduce this healthcare burden, it is essential that those at high risk of BPD are identified early so that strategies are introduced to prevent disease progression. Our aim was to discuss potential methods for improving early diagnosis in the first week after birth.Areas covered: A narrative review was undertaken. The search strategy involved searching PubMed, Embase and Cochrane databases from 1967 to 2024. The results of potential biomarkers and imaging modes are discussed. Furthermore, the value of scoring systems is explored.Expert opinion: BPD occurs as a result of disruption to pulmonary vascular and alveolar development, thus abnormal levels of factors regulating those processes are promising avenues to explore with regard to early detection of high-risk infants. Data from twin studies suggests genetic factors can be attributed to 82% of the observed difference in moderate to severe BPD, but large genome-wide studies have yielded conflicting results. Comparative studies are required to determine which biomarker or imaging mode may most accurately diagnose early BPD development. Models which include the most predictive factors should be evaluated going forward.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"283-294"},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141322187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0